CLAIM AMENDMENTS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. **(Currently Amended)** A compound according to formula I



(I)

wherein

P is ~~selected from aryl and heteroaryl~~ phenyl;

R^1 is attached to P via a carbon atom on ring P and is selected from the group consisting of ~~hydroxy~~ hydrogen, halo, ~~nitro,~~ C_{1-6}alkylhalo, OC_{1-6}alkylhalo, C_{1-6}alkyl, OC_{1-6}alkyl, C_{1-6}alkylOR^5, C_{0-6}alkylcyano and C_{0-6}alkylNR^5R^6, ~~C_{2-6}alkenyl, OC_{2-6}alkenyl, C_{2-6}alkynyl, OC_{2-6}alkynyl, C_{0-6}alkylC_{3-6}cycloalkyl, OC_{0-6}alkylC_{3-6}cycloalkyl, C_{0-6}alkylaryl, OC_{0-6}alkylaryl, CHO, $(CO)R^5$, $O(CO)R^5$, $O(CO)OR^5$, $O(CNR^5)OR^5$, C_{1-6}alkylOR^5, OC_{2-6}alkylOR^5, C_{1-6}alkyl$(CO)R^5$, OC_{1-6}alkyl$(CO)R^5$, C_{0-6}alkylCO_2R^5, OC_{1-6}alkylCO_2R^5, C_{0-6}alkylcyano, OC_{2-6}alkylcyano, C_{0-6}alkylNR^5R^6, OC_{2-6}alkylNR^5R^6, C_{1-6}alkyl$(CO)NR^5R^6$, OC_{1-6}alkyl$(CO)NR^5R^6$, C_{0-6}alkyl$NR^5(CO)R^6$, OC_{2-6}alkyl$NR^5(CO)R^6$, C_{0-6}alkyl$NR^5(CO)NR^5R^6$, C_{0-6}alkylSR^5, OC_{2-6}alkylSR^5, C_{0-6}alkyl$(SO)R^5$, OC_{2-6}alkyl$(SO)R^5$, C_{0-6}alkylSO_2R^5, OC_{2-6}alkylSO_2R^5, C_{0-6}alkyl$(SO_2)NR^5R^6$, OC_{2-6}alkyl$(SO_2)NR^5R^6$, C_{0-6}alkyl$NR^5(SO_2)R^6$, OC_{2-6}alkyl$NR^5(SO_2)R^6$, C_{0-6}alkyl$NR^5(SO_2)NR^5R^6$, OC_{2-6}alkyl$NR^5(SO_2)NR^5R^6$, $(CO)NR^5R^6$, $O(CO)NR^5R^6$, NR^5OR^6, C_{0-6}~~

~~$_6$alkylNR^5(CO)OR^6, OC$_{2-6}$alkylNR^5(CO)OR^6, SO$_3$R^5 and a 5- or 6-membered ring containing atoms independently selected from the group consisting of C, N, O and S;~~

X^1 is selected from the group consisting **[[**of:**]]** of N, NR^4 and CR^4;

X^2 is selected from the group consisting **[[**of:**]]** of C and N;

X^3 is selected from the group consisting **[[**of: CR^4,**]]** of N and O;

X^4 is selected from the group consisting **[[**of:**]]** of CR^4, N, NR^4 and O;

X^5 is selected from the group consisting **[[**of:**]]** of a bond, $CR^4R^{4'}$, NR^4, O, S, SO and SO_2;

X^6 is ~~selected from the group consisting of: CR^4 and~~ N;

X^7 is selected from the group consisting **[[**of:**]]** of C and N;

R^4 and $R^{4'}$ are independently selected from the group consisting of hydrogen, halo, C_{1-6}alkyl and C_{1-6}alkylhalo;

Q is triazolyl;

~~R^4 is independently selected from a group consisting of hydrogen, hydroxy, C$_{1-6}$alkyl, C$_{0-6}$alkylcyano, oxo, =NR^5, =NOR^5, C$_{1-4}$alkylhalo, halo, C$_{3-7}$cycloalkyl, O(CO)C$_{1-4}$alkyl, C$_{1-4}$alkyl(SO)C$_{0-4}$alkyl, C$_{1-4}$alkyl(SO$_2$)C$_{0-4}$alkyl, (SO)C$_{0-4}$alkyl, (SO$_2$)C$_{0-4}$alkyl, OC$_{1-4}$alkyl, C$_{1-4}$alkylOR^5 and C$_{0-4}$alkylNR^{5}R^6;~~

~~Q is selected the group consisting of heterocycloalkyl and heteroaryl;~~

R^2 and R^3 are independently selected from the group consisting **[[**of:**]]** of hydroxy, C_{0-6}alkylcyano, oxo, $=NR^5$, $=NOR^5$, C_{1-4}alkylhalo, halo, C_{1-6}alkyl, C_{3-6}cycloalkyl, C_{0-6}alkylaryl, C_{0-6}alkylheteroaryl, C_{1-6}alkylcycloalkyl, C_{0-6}alkylheterocycloalkyl, OC_{1-4}alkyl, OC_{0-6}alkylaryl, $O(CO)C_{1-4}$alkyl, $(CO)OC_{1-4}$alkyl, C_{0-4}alkyl(S)C_{0-4}alkyl, C_{1-4}alkyl(SO)C_{0-4}alkyl, C_{1-4}alkyl(SO_2)C_{0-4}alkyl, (SO)C_{0-4}alkyl, (SO_2)C_{0-4}alkyl, C_{1-4}alkylOR^5, C_{0-4}alkylNR^{5}R^6 and a 5- or 6-membered ring containing atoms independently selected from C, N, O and S, which ring may

optionally be fused with a 5- or 6-membered ring containing atoms independently selected from the group consisting of C, N and O and wherein said ring and said fused ring may be substituted by one or more A;

wherein any C_{1-6}alkyl, aryl, or heteroaryl defined under R^1, R^2 and R^3 may be substituted by one or more A;

A is selected from the group consisting of: hydrogen, hydroxy, halo, nitro, oxo, C_{0-6}alkylcyano, C_{0-4}alkylC_{3-6}cycloalkyl, C_{1-6}alkyl, -OC_{1-6}alkyl, C_{1-6}alkylhalo, OC_{1-6}alkylhalo, C_{2-6}alkenyl, C_{0-3}alkylaryl, C_{0-6}alkylOR^5, OC_{2-6}alkylOR^5, C_{0-6}alkylSR^5, OC_{2-6}alkylSR^5, $(CO)R^5$, $O(CO)R^5$, OC_{2-6}alkylcyano, OC_{1-6}alkylCO_2R^5, $O(CO)OR^5$, OC_{1-6}alkyl$(CO)R^5$, C_{1-6}alkyl$(CO)R^5$, NR^5OR^6, $C_{0-6}NR^5R^6$, OC_{2-6}alkylNR^5R^6, C_{0-6}alkyl$(CO)NR^5R^6$, OC_{1-6}alkyl$(CO)NR^5R^6$, OC_{2-6}alkyl$NR^5(CO)R^6$, C_{0-6}alkyl$NR^5(CO)R^6$, C_{0-6}alkyl$NR^5(CO)NR^5R^6$, $O(CO)NR^5R^6$, C_{0-6}alkyl$(SO_2)NR^5R^6$, OC_{2-6}alkyl$(SO_2)NR^5R^6$, C_{0-6}alkyl$NR^5(SO_2)R^6$, OC_{2-6}alkyl$NR^5(SO_2)R^6$, SO_3R^5, C_{1-6}alkyl$NR^5(SO_2)NR^5R^6$, OC_{2-6}alkyl$(SO_2)R^5$, C_{0-6}alkyl$(SO_2)R^5$, C_{0-6}alkyl$(SO)R^5$, OC_{2-6}alkyl$(SO)R^5$ and a 5- or 6-membered ring containing atoms independently selected from the group consisting of C, N, O and S;

R^5 and R^6 are independently selected from, H, C_{1-6}alkyl, C_{3-7}cycloalkyl and aryl;

m is ~~selected from 0, 1, 2, 3 or 4~~ 1 or 2;

n is selected from 0, 1, 2, 3 or 4;

p is selected from 0, 1, 2, 3 or 4; **[[**and**]]** or

~~a salt or hydrate thereof,~~

~~with the proviso that the compound is not:~~

~~4,4'-(1,2-piperazinediyl)di-antipyrine;~~

~~4,4'-(1,2-piperazinediyl)di-antipyrine dihydrochloride; or~~

~~4,4'-(1,2-piperazinediyl)di-antipyrine dipicrate;~~

a pharmaceutically acceptable salt thereof.

2. **(Canceled)**

3. **(Original)** A compound according to claim 1 wherein X^7 is C.

4. **(Withdrawn)** A compound according to claim 1 wherein X^5 is selected from the group consisting of $CR^4R^{4'}$, NR^4, O, S, SO and SO_2.

5-9. **(Canceled)**

10. **(currently amended)** A compound according to claim **[[9]]** 1 wherein R^1 is selected from the group consisting of: Cl, F, Me, OMe, CF_3, OCF_3, and CN.

11. **(Original)** A compound according to claim 1 wherein X^2 is C.

12. **(Original)** A compound according to claim 11 wherein X^1 is N or CR^4.

13. **(Original)** A compound according to claim 12 wherein when X^3 is O, X^4 is N and when X^3 is N, X^4 is O.

14. **(Original)** A compound according to claim 1 wherein X^2 is N.

15. **(Original)** A compound according to claim 14 wherein X^1 is N.

16. **(Original)** A compound according to claim 15 wherein X^3 is N and X^4 is N or CR^4.

17. **(Canceled)**

18. **(Original)** A compound according to claim 12 wherein X^5 is selected from the group consisting of a bond, $CR^4R^{4'}$, NR^4 and O.

19. **(Original)** A compound according to claim 13 wherein X^5 is selected from the group consisting of a bond, O and NR^4.

20. **(Withdrawn)** A compound according to claim 16 wherein X^5 is selected from the group consisting of O and CR^4.

21-24. **(Canceled)**

25. **(Currently amended)** A compound according to claim 1 wherein R^2 and R^3 are independently selected from the group consisting [[of:]] <u>of</u> C_{1-4}alkylhalo, C_{1-6}alkyl, C_{3-6}cycloalkyl, C_{0-6}alkylaryl and C_{0-6}alkylheteroaryl.

26. **(Currently amended)** A compound according to claim 1 wherein A is selected from the group consisting [[of:]] of hydrogen, hydroxyl, halo, C_{0-6}alkylcyano, C_{1-6}alkyl, -OC_{1-6}alkyl, C_{1-6}alkylhalo, OC_{1-6}alkylhalo.

27. **(Currently Amended)** A compound according to claim 1 selected from:

4-(5-{2-[5-(3-Chloro-phenyl)-isoxazol-3-yl]-piperidin-1-yl}-4-methyl-4H [1,2,4]triazol-3-yl)-pyridine,

3-[5-(3-Chloro-phenyl)-isoxazol-3-yl]-4-(4-methyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-morpholine,

3-[5-(3-Chloro-phenyl)-isoxazol-3-yl]-4-[5-(4-difluoromethoxy-phenyl)-4-methyl-4H-[1,2,4]triazol-3-yl]-morpholine,

3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-4-(4-methyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-morpholine,

3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-4-[5-(4-difluoromethoxy-phenyl)-4-methyl-4H-[1,2,4]triazol-3-yl]-morpholine,

3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-4-(4-methyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-piperazine-1-carboxylic acid tert-butyl ester,

2-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-1-(4-methyl-5-pyridin-4-yl-4H-1,2,4]triazol-3-yl)-piperazine,

2-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-4-methyl-1-(4-methyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-piperazine,

3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-4-[5-(4-difluoromethoxy-phenyl)-4-methyl-4H-[1,2,4]triazol-3-yl]-piperazine-1-carboxylic acid tert-butyl ester,

2-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-1-[5-(4-difluoromethoxy-phenyl)-4-methyl-4H-[1,2,4]triazol-3-yl]-piperazine,

2-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-1-[5-(4-difluoromethoxy-phenyl)-4-methyl-4H-[1,2,4]triazol-3-yl]-4-methyl-piperazine,

2-[2-(3-Chlorophenyl)-2H-tetrazol-5-yl]-1-{5-[4-(difluoromethoxy)phenyl]-4-methyl-4H-1,2,4-triazol-3-yl}piperidine,

4-(5-{2-[2-(3-chlorophenyl)-2H-tetrazol-5-yl]piperidin-1-yl}-4-methyl-4H-1,2,4-triazol-3-yl)pyridine,

2-[2-(3-Chlorophenyl)-2H-tetrazol-5-yl]-1-[5-(4-methoxyphenyl)-4-methyl-4H-1,2,4-triazol-3-yl]piperidine,

[4-(5-{2-[2-(3-chlorophenyl)-2H-tetrazol-5-yl]piperidin-1-yl}-4-methyl-4H-1,2,4-triazol-3-yl)phenyl]dimethylamine,

[4-(5-{2-[2-(3-Chloro-phenyl)-2H-tetrazol-5-yl]-piperidin-1-yl}-4-methyl-4H-[1,2,4]triazol-3-yl)-benzyl]-dimethyl-amine,

{2-[4-(5-{2-[2-(3-Chloro-phenyl)-2H-tetrazol-5-yl]-piperidin-1-yl}-4-methyl-4H-[1,2,4]triazol-3-yl)-phenoxy]-ethyl}-dimethyl-amine,

(R)-3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-4-(4-methyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-morpholine,

(S) 3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-4-(4-methyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-morpholine,

(R)-2-[2-(3-Chlorophenyl)-2H-tetrazol-5-yl]-1-{5-[4-(difluoromethoxy)phenyl]-4-methyl-4H-1,2,4-triazol-3-yl}piperidine,

(S)-2-[2-(3-Chlorophenyl)-2H-tetrazol-5-yl]-1-{5-[4-(difluoromethoxy)phenyl]-4-methyl-4H-1,2,4-triazol-3-yl}piperidine,

(R)-4-(5-{2-[2-(3-Chlorophenyl)-2H-tetrazol-5-yl]piperidin-1-yl}-4-methyl-4H-1,2,4-triazol-3-yl)pyridine,

(S)-4-(5-{2-[2-(3-Chlorophenyl)-2H-tetrazol-5-yl]piperidin-1-yl}-4-methyl-4H-1,2,4-triazol-3-yl)pyridine,

4-[5-(5-{2-[5-(3-Chloro-phenyl)-isoxazol-3-yl]-pyrrolidin-1-yl}-4-cyclopropyl-4H-[1,2,4]triazol-3-yl)-pyridin-2-yl]-morpholine,

4-[5-(5-{2-[5-(3-Chloro-phenyl)-isoxazol-3-yl]-pyrrolidin-1-yl}-4-methyl-4H-[1,2,4]triazol-3-yl)-pyridin-2-yl]-morpholine,

3-(5-{2-[5-(3-Chloro-phenyl)-isoxazol-3-yl]-pyrrolidin-1-yl}-4-methyl-4H-[1,2,4]triazol-3-yl)-pyridine,

4-(5-{2-[5-(3-Chloro-phenyl)-isoxazol-3-yl]-pyrrolidin-1-yl}-4-cyclopropyl-4H-[1,2,4]triazol-3-yl)-pyridine,

3-[5-(3-Chloro-phenyl)-[1,2,4]oxadioazol-3-yl]-4-(5-pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-morpholine,

3-[5-(3-chlorophenyl)isoxazol-3-yl]-4-(4- cyclopropyl-5-pyridin-3-yl-4H-1,2,4-triazol-3-yl)morpholine,

3-[5-(3-chlorophenyl)isoxazol-3-yl]-4-(4- cyclopropyl -5-pyridin-4-yl-4H-1,2,4-triazol-3-yl)morpholine,

3-[5-(3-chlorophenyl)isoxazol-3-yl]-4-(4-methyl-5-pyridin-3-yl-4H-1,2,4-triazol-3-yl)morpholine,

3-[5-(3-Chloro-phenyl)-isoxazol-3-yl]-4-[5-(6-methoxy-pyridin-3-yl)-4-methyl-4H-[1,2,4]triazol-3-yl]-morpholine,

3-[3-(3-chlorophenyl)-1,2,4-oxadiazol-5-yl]-4-[5-(2-methoxypyridin-4-yl)-4-methyl-4H-1,2,4-triazol-3-yl]morpholine,

3-[3-(3-chlorophenyl)-1,2,4-oxadiazol-5-yl]-4-[5-(2-methylpyridin-4-yl)-4-methyl-4H-1,2,4-triazol-3-yl]morpholine,

3-[3-(3-chlorophenyl)-1,2,4-oxadiazol-5-yl]-4-[5-(5-fluoropyridin-3-yl)-4-methyl-4H-1,2,4-triazol-3-yl]morpholine,

3-[5-(3-chlorophenyl)isoxazol-3-yl]-4-[5-(5-fluoropyridin-3-yl)-4-methyl-4H-1,2,4-triazol-3-yl]morpholine,

3-[3-(3-chlorophenyl)-1,2,4-oxadiazol-5-yl]-4-(4-methyl-5-pyridin-2-yl-4H-1,2,4-triazol-3-yl)morpholine,

4-[5-(5-fluoropyridin-3-yl)-4-methyl-4H-1,2,4-triazol-3-yl]-3-[3-(3-iodophenyl)-1,2,4-oxadiazol-5-yl]morpholine,

3-[3-(3-iodophenyl)-1,2,4-oxadiazol-5-yl]-4-(4-methyl-5-pyridin-4-yl-4H-1,2,4-triazol-3-yl)morpholine,

3-[5-(3-chlorophenyl)isoxazol-3-yl]-4-[5-(2-methylpyridin-4-yl)-4-methyl-4H-1,2,4-triazol-3-yl]morpholine,

3-[2-(3-chlorophenyl)-2H-tetrazol-5-yl]-4-(4-methyl-5-pyridin-3-yl-4H-1,2,4-triazol-3-yl)morpholine,

3-[2-(3-chlorophenyl)-2H-tetrazol-5-yl]-4-[5-(3,5-difluorophenyl)-4-methyl-4H-1,2,4-triazol-3-yl]morpholine,

3-(5-{2-[5-(3-chlorophenyl)isoxazol-3-yl]pyrrolidin-1-yl}-4-cyclopropyl-4H-1,2,4-triazol-3-yl)pyridine, and

4-(5-{2-[5-(3-chlorophenyl)isoxazol-3-yl]pyrrolidin-1-yl}-4-methyl-4H-1,2,4-triazol-3-yl)pyridine.

28. **(Currently amended)** A pharmaceutical composition comprising as active ingredient a therapeutically effective amount of the compound according to any one of claims [[1

to 26,]] 1, 3, 4, 10-16, 18-20, 25 and 26, in association with one or more pharmaceutically acceptable diluent, excipients and/or inert carrier.

29. **(Canceled)**

30. **(Previously Presented)** The compound according to claim 1, for use in therapy.

31. **(Previously Presented)** The compound according to claim 1, for use in treatment of mGluR 5 mediated disorders.

32. **(Withdrawn)** Use of the compound according to claim 1, in the manufacture of a medicament for the treatment of mGluR 5 mediated disorders.

33. **(Currently Amended - Withdrawn)** A method of treatment of mGluR 5 mediated disorders, comprising ~~administrering~~ administering to a mammal, including man in need of such treatment, a therapeutically effective amount of the compound according to claim 1.

34. **(Currently Amended - Withdrawn)** The method according to claim 33, ~~for use in treatment of~~ wherein the disorders mediated by mGluR 5 are neurological disorders.

35. **(Currently Amended - Withdrawn)** The method according to claim 33, ~~for use in treatment of~~ wherein the disorders mediated by mGluR 5 are psychiatric disorders.

36. **(Currently Amended - Withdrawn)** The method according to claim 33, ~~for use in treatment of~~ wherein the disorders mediated by mGluR 5 are chronic and acute pain disorders.

37. **(Currently Amended - Withdrawn)** The method according to claim 33, ~~for use in treatment of~~ wherein the disorders mediated by mGluR 5 are gastrointestinal disorders.

38. **(Withdrawn)** A method for inhibiting activation of mGluR 5 receptors, comprising treating a cell containing said receptor with an effective amount of the compound according to claim 1.